Showing posts with label Transparency Market Research. Show all posts
Showing posts with label Transparency Market Research. Show all posts

Monday, 19 October 2015

Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S

02:31 No comments
Spinal muscular atrophy (SMA) is a hereditary autosomal recessive disease affecting areas of the nervous system that control voluntary muscle movement. SMA is identified as a leading genetic disorder causing mortality among infants. According to Orphanet, one infant in 6,000 births is estimated to suffer from SMA. Furthermore, over 10 million people in the U.S. are carriers of SMA gene. Depending on the age of onset and symptoms, spinal muscular atrophy is classified in four main types. Type 1 SMA is the most severe form, and affects infants aged between zero and six months. Over 60% of annual SMA cases are of type 1 SMA, wherein infants usually do not survive for more than 2 years. Type 2 SMA is a moderate form affecting children aged between six months and eighteen months. Patients with Type 3 SMA and Type 4 SMA usually have a normal lifespan.
spinal-muscular-atrophy-market
Currently, no cure exists for spinal muscular atrophy, and treatment is directed towards managing common symptoms of SMA. Physiotherapy is strongly recommended in early stages of the disease to extend range of motion and improve muscle flexibility. Other treatment methods are targeted to treat gastrointestinal and respiratory disorders, which are common in SMA patients. The SMA pipeline is dry, with single drug in phase 3, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx by Isis Pharmaceutical is an antisense drug that has shown promising results in phase 2 clinical trials. Phase 3 study of ISIS-SMNRx for treatment of Type 1 SMA and Type 2 SMA is expected to complete in 2016. In the United States, the drug is expected to reach annual sales of USD 0.47 billion by 2023. Olesoxime (TRO19622) has completed its phase2/3 trials, and has shown promising results, with potential to effectively treat type 2 and type 3 SMA. Other potential candidates include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.

The United States and Europe have higher percentage of diagnosed cases of SMA. Government and private organization in these regions are also involved in creating awareness about the disease. Higher confirmed carrier population would also help in faster market growth in these regions. Furthermore, government incentives for development of therapeutic alternatives for rare diseases also boosts research and development in the SMA landscape.Companies with potential candidates in the spinal muscular atrophy pipeline include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc.   

Spinal Muscular Atrophy Pipeline is segmented as below:
Late Stage Candidates (Phase 3)
ISIS-SMN Rx

Early Stage Candidates (Phase 1 and Phase 2)
Olesoxime (TRO19622)
LMI070
RO6885247
CK-2127107
CB.SMN
RG3039

Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187
Read More

Wednesday, 26 August 2015

Nanocapsules Market Segment Forecasts up to 2023

07:06 No comments
Nanocapsules are drug delivery agents within the size range of 10nm to 1000 nm that are normally composed of a capsule shell and a hollow space in which desired substance or drug molecules are embedded. The ultrafine size of nanocapsules match the biological composition of human body such as RBCs which permits enhanced permeation and retention (EPR) through narrow channels during diffusion. Due to this EPR effect, nanocapsules are used as drug carriers. Nanocapsules can be formulation using various methods such as loading of drug molecules into hollow polyelectrolyte shell and another method being electrostatic layer by layer (LbL) technique. These latest LbL self-assembled polyelectrolyte capsules provide an efficient way to perform multiple drug delivery tasks simultaneously. Some nanocapsules are used for targeted drug delivery in anti-tumor and anti-tuberculosis therapies wherein the outer sphere of nanocapsules is fabricated by the lithography technique. Lipid nanocapsules (DNA LNCs) and multimodular systems (DNA MMS) are used in gene therapy.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/nanocapsules-market.html

Global investment in nanotechnology research has witnessed a six fold increase during the last decade. Consequently, nanotechnology will completely revolutionize the industrial processes in the near future due to its remarkable economic potential. Some of the key drivers for the market growth include investments and breakthroughs in biomedical, pharmaceutical, electronics, molecular and diagnostic fields. Besides, these nanocapsules are being increasingly used in agrochemicals, environment and wastewater treatments, genetic engineering, consumer goods and cosmetic procedures. Some of the most advanced future applications would be nanocapsule dressings to deliver antibiotics aiding faster wound healing without invasion to the skin. These nanocapsule bandages would be consistently demanded by defence and protection forces as they need not be changed periodically. According to the experts, electronics and magnetic sector will be the largest potential market for nanocapsules, followed by biopharmaceutical industry, catalysis, energy and engineering. However, growth in the nanocapsules market will also pose new challenges with respect to the toxicity and environmental impact of nanocapsules. Recently efforts have been made to overcome these drawbacks by developing eco-friendly versatile nanocapsules. For instance, nanocapsules introduced by the Center for Self-assembly and Complexity, Institute for Basic Science (IBS). Other factors such as cost escalation and consequences on the global economy especially in cases of under-developed economies with poor R&D investment would exhibit low social and ethical acceptance of nanocapsules.

Funding for nanotechnology is soaring worldwide at a competitive level, with each major economic power and many developed economies making a substantial investment to revamp their industrial and postindustrial supply chains. Technological inventions and discoveries in nanotechnology would cause tremendous growth in the global nanocapsule market. Due to a variety of potential applications, nanotechnology is expected to become the key technology in the near future. U.S. has invested around USD 3.7 billion through its National Nanotechnology Initiative for research activities. The European Union had spent approximately USD 1.2 billion and Japan USD 750 million by 2012. Moreover, there is a steady demand for medically advanced procedures in developed as well as developing regions having a well-established healthcare infrastructure. In the Asia Pacific region, the demand for nanocapsules is projected to rise owing to the high disease burden of tuberculosis and cancer. Some of the key factors that are likely to contribute toward the market growth are growing awareness about genetic counselling, genetic disorders, high prevalence of tuberculosis and multi-drug resistant tuberculosis, increasing trend in cancer and tumor ailments and surging demand for oncological treatments.

Presently, nanocapsules are under different stages of clinical trial phases facing several hurdles to gain market entry. However, few commercially available nanocapsules which are now commercially used as several pigments in sunscreen, scratch resistance coatings, catalysts, and biomarkers. Some of the key market players for these commercially available nanocapsules are Abraxis, Artificial Cell Technologies, Inc., BioDelivery Sciences International, Inc., Biophan Technologies, Inc., Cornerstone Pharmaceuticals, Inc., Genetic Immunity, Inc., Keystone Nano, Inc., Makefield Therapeutics, Inc., Nanospectra Biosciences, Inc., and Mersana Therapeutics, Inc.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:-
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Get Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5321

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Read More

Monday, 24 August 2015

Ischemia Market Segment Forecasts up to 2020

07:29 No comments

Ischemia is characterized by a specific condition, where there is an insufficient flow of blood supply to tissues, leading to a shortage of oxygen and glucose which is needed for cellular metabolism. Due to an obstruction and insufficient blood supply, various organs and tissue get severely damaged. Ischemia, if left untreated, may lead to tissue death. Ischemia is primarily caused by thrombosis of an artery, embolism, vasculitis, atherosclerosis, coronary artery disease and peripheral artery disease. There are various types of ischemia with different diagnosis and treatment methods involved with each type of ischemia. 


Based on the types, ischemia market can be segmented as follows:
  • Myocardial ischemia: Due to blockage of a coronary artery, there is a limited blood flow to the heart muscle and is referred to as myocardial ischemia. Symptoms include arm pain, chest pain, breathlessness, dizziness, weakness, heart palpitations and clammy skin.
  • Cerebral ischemia: Cerebral ischemia occurs when there is a temporary deficiency of blood supply to an individual’s brain. Symptoms include difficulty in speaking, lack of coordination, body movement problems, vision impairment and unconsciousness.
  • Intestinal ischemia: Ischemia affects intestine too, and this condition is known as intestinal ischemia. Various symptoms include abdominal pain, fever, diarrhea, vomiting, bloody stools and weight loss.
  • Hepatic ischemia: In hepatic ischemia, an individual’s liver does not receive enough blood supply. Hypotension is the prime cause of hepatic ischemia and symptoms include dehydration, heart failure, severe bleeding and abnormal heart rhythms. 
  • Acute limb ischemia: Decreased level of blood flow to hands, feet and legs leads to acute limb ischemia. Symptoms include skin ulcers, skin sores and severe pain.
Based on treatment, the ischemia can be segmented as follows:
  • Medications:
    • Angiotensin-converting enzyme (ACE) inhibitors
    • Anticoagulants
    • Aspirin
    • Analgesics
    • Beta blockers
    • Nitroglycerine
  • Surgery methods:
    • Angioplasty, also referred to as percutaneous coronary intervention (PCI)
    • Coronary artery bypass surgery
    • Embolectomy
    • Aortomesenteric bypass and resection of bowel
Based on geography, the ischemia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Out of these regions, North America dominates the ischemia market followed by Europe. The prime factors which would drive the growth of the market in these regions are growing prevalence of high cholesterol diseases, increasing incidences of obesity and physical inactivity. Moreover, technological advancements and increasing competition from small market players have further fueled the growth of ischemia market. According to a survey, approximately 1.5 million cases of myocardial ischemia occur annually in the United States. Moreover, technological advancements and increasing competition from small market players have further fueled the growth of ischemia market. Asia Pacific is one of the most promising markets for the growth of ischemia market due to easy market penetration. 

The factors which would augment the growth of the market in Asia Pacific are increasing geriatric population, high prevalence of unhealthy lifestyle amongst the population and increasing awareness regarding the malignant effects of ischemia. Other factors such as tax benefits and increasing disposable incomes of the population would further propel the growth of ischemia market.


Various biopharmaceutical companies are constantly coming up with novel therapeutics for the treatment of ischemia. Some of the top players operating in the ischemia market are Sanofi, Pfizer, Inc., Medicure, Inc., Baxter International, Boston Scientific Corporation, Vasade Biosciences, Inc. and others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
    

About Us:-
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:-
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Read More

Tuesday, 17 June 2014

Neuromodulation Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast 2012 - 2018

02:03 No comments
According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018 " the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

Browse the  Neuromodulation Devices Market report with full TOC at http://www.transparencymarketresearch.com/global-neuromodulation-devices-market.html

The market is driven by factors such as the aging world population leading to chronic diseases such as Parkinson´s and Alzheimer´s disorders and technological advancements in the field of neuromodulation devices including the invention of transversal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.


The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.

Read More

Monday, 16 June 2014

Nutraceutical Ingredients Market is Expected to Reach USD 29.5 Billion Globally in 2017: Transparency Market Research

04:27 No comments
According to a new market report published by Transparency Market Research "Nutraceutical Ingredients Market - Global Industry Analysis, Market Size, Share, Growth And Forecast 2007 - 2017", global nutraceutical ingredients market is expected to be worth USD 20.8 billion in 2012 and is further expected to reach USD 29.5 billion in 2017, growing at a CAGR of 7.3% from 2012 to 2017. The body building segment is expected to be the largest segment at USD 9.5 billion in 2012. In the overall global market, Asia Pacific region is expected to maintain its lead position in terms of revenue till 2017. Asia Pacific is expected to enjoy 37.5% of global nutraceutical ingredients market revenue share in 2017 followed by North America.

Browse the Nutraceutical Ingredients Market report with full TOC athttp://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

Increasing number of clinical studies confirming the health benefits of nutraceuticals and their broad applications in food, beverages, dietary supplements, and pediatric and adult nutritional preparations has provided support for the growing use of nutraceutical ingredients. Moreover, faster growth in consumption of nutraceutical ingredients worldwide, especially in developing economies has boosted the growth of nutraceutical ingredient market. In addition, increasing economic prosperity in developing countries including India, China, Brazil, Mexico, Russia,South Africa, South Koreaand Poland will enable consumers to spend more on health and nutrition. This will boost the future growth of the nutraceutical ingredient market.


Major segments of nutraceutical ingredients market include Body building, weight control, diabetes control and pain relief. In 2011, body building was the largest segment followed by weight control. The controlling diabetes segment was the third largest segment, accounting for 16.5% revenue share in 2011.
Amino acids and soy-based ingredients segments of body building market witnessed healthy growth rate during the review period (from 2007 to 2011). The growth in amino acid & soy-based ingredient segment is largely attributed to increased trend of fitness in most of the developing nations. The protein and peptide segment is also expected to have steady growth rate because of growing demand for nutritional diet and proper physic all over the world.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Nutraceutical ingredients presents opportunity for new entrants as well for existing players, due to the fact that most of the raw materials are abundant and product manufacturers are increasingly focusing on contract manufacturing outsourcing (CMO). Moreover, large product manufacturers are looking for backward integration, which will grow the competition into the market and will intern increase the market size of the nutraceutical ingredients.
This report is an effort to identify factors, which will be the driving force behind the nutraceutical ingredient market and its sub-markets over the next six years. The report provides extensive analysis of the nutraceutical industry, current market trends for better understanding of the nutraceutical ingredient market.

Read More

Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

02:34 No comments
According to a new market report published by Transparency Market Research, "Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global enteric disease testing market was valued at USD 3.1 billion in 2012 and is expected to grow at a CAGR of 2.4% from 2013 to 2019, to reach an estimated value of USD 3.6 billion in 2019.


Enteric diseases are major causes of morbidity and mortality worldwide. Developing socio-economic countries with poor drainage, sanitation along with overcrowding and low hygiene awareness account for majority of enteric infection incidences prevailing worldwide. These diseases usually exhibit mild symptoms but if not treated on time can lead to severe complications, resulting in death. In order to manage these diseases effectively, their early detection is essential. Various enteric diseases responsible for diarrhea, stomach pain, nausea, vomiting, anorexia, weight loss and fever are amebiasis, giardiasis, rotavirus infection, salmonellosis and shigellosis.


Traditionally, diagnosis of enteric infections relied on culture results of fecal specimen. Today, the world is witnessing a paradigm shift from culture to EIA (enzyme immunoassaya) and PCR (polymerase chain reaction) based tests owing to advantages associated with these newer testing methods. EIA and PCR tests offer enhanced sensitivity and specificity compared to culture tests and also give quick results. Globally the market for enteric disease testing is growing at a CAGR of 2.4% under the influence of rising awareness, demand for point of care testing and increasing application of molecular diagnostics. Use of molecular diagnostic products has made diagnosis easy and possible, even those strains which once seemed to be difficult and impossible. North America and Europe represent the largest regional markets because of rapid demand for molecular based diagnostics and due to high level of awareness among people about the diseases. C.difficile infection is one of the major causes of antibiotic related diarrhea in developed regions.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Various epidemiological sources including CDC and American Association for Clinical Chemistry suggest that C.difficile infection incidence per 100,000 people has increased over the past few decades in United States. In developing nations, frequent travelling to regions where enteric diseases are epidemic is also one of the reasons driving the market growth. Asia-Pacific and Africa have been predicted to grow rapidly during the forecast period. In developing nations of Asia-pacific, Africa and Latin America, the market is also growing due to advent of rapid dipstick tests which can be applied by the patient themself. These regions associated with inadequate healthcare infrastructure do not possess substantial number of laboratories to perform laboratory based tests. Thus, rapid dipstick test kits being inexpensive and easy to use are widely accepted in these regions for managing enteric illness. Continuously improving economy and rising healthcare expenditure in these regions are also anticipated to drive the market. The market is also growing due to emergence of new strains; sources from Eurosurveillance suggest that the norovirus infection is increasing worldwide, including United Kingdom, the Netherlands, France, Japan and Australia due to emergence of new strain of genotype II.4 (GII.4) that is also known as Sydney strain.

Read More

Pain Management Therapeutics Market is expected to Decline to USD 29.47 Billion Globally by 2018: Transparency Market Research

00:02 No comments
According to a new market report published by Transparency Market Research "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

Browse the Pain Management Therapeutics Market Research report with full TOC at http://www.transparencymarketresearch.com/pain-management-therapeutics.html

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.
Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.


The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.
The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

Read More

Friday, 13 June 2014

Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast 2012 – 2018

04:36 No comments
According to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018", the global liver diseases therapeutics market was worth USD 6.5 billion in 2011 and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6% from 2012 to 2018. In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018.

Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html 

The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.

Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799

Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.

Read More

Insulin Market Expected to Reach USD 32,346.7 Million in 2018 - Transparency Market Research

00:03 No comments
Insulin Market
According to a new market report published by Transparency Market Research "Insulin Market - Global and China Scenario, Trends, Industry Analysis, Size, Share and Forecast, 2011 - 2018" the global insulin market was worth USD 12,476.3 million in 2011 and is expected to reach USD 32,346.7 million in 2018, growing at a CAGR of 12% from 2011 to 2018. In the global market, China is expected to increase its share in the global insulin market to 10.2% by 2018.
The global insulin market is driven by rise in diabetic population worldwide. The world diabetes population was estimated at 366 million in the year 2011, and is expected to reach 552 million in 2030. It is estimated that diabetes accounts for 4.6 million deaths, with cases of people dying due to lack of insulin and not even being diagnosed.

This however, presents a huge supply demand deficit for insulin, with high growth potential in developing markets. The factors contributing to the insulin market growth also includes increase in global expenditure on healthcare, strong distribution network, and high scope in developing economies such as China and India.

Browse the full Insulin Market Report at http://www.transparencymarketresearch.com/insulin-market.html

It is estimated that worldwide, by year 2030, one in ten people will suffer from diabetes, giving rise to huge demand for insulin. China, being the most populous nation in the world, accounts for the largest share of the global diabetic population and eventually turns out as the most lucrative market for insulin manufacturers.

Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=259

The China insulin market is projected to grow at a CAGR twice that of the global insulin market. It was estimated at USD 723.8 million in 2011, and is projected to reach USD 3,299.1 million in the year 2018, growing at a CAGR of 24.6%. Currently, China accounts for 6.1% of the global insulin market in terms of volume, which was estimated at 22.4 tMU in 2011. The global insulin market by volume is projected to grow at a CAGR of 7.9% from 2012 - 2018.

Browse Blog http://tmrresearch.wordpress.com/

The global insulin market has continuously witnessed new advanced product types being introduced in the market by insulin manufacturers. The recent product type is modern insulin, which is a genetically engineered version of human insulin, and has been selectively modified to counter the issues associated with human insulin. Currently, modern insulin accounts for more than 76% of the global insulin market.
To meet the rising demand, global insulin manufacturers are not only augmenting existing production facilities, but also expanding their global presence to meet the supply demand gap. Leading insulin manufacturers are now focusing on reinforcing their market leadership in China. It includes key global and China insulin market players such as Novo Nordisk, Sanofi-Aventis, and Eli-Lilly. Together they account for more than 90% of the global insulin market share.

Browse all Pharmaceutical Research Report at http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


This research is specially designed to estimate and analyze the demand and performance of the global and China insulin market in the current market scenario. This research provides in-depth analysis of insulin manufacturers, product sales, trend analysis by segments, and demand by geography. The report covers all the major product segments of the global and China insulin market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. 

Download PDF at Insulin Market - Global And China Industry Analysis, Size, Share, Growth, And Forecast 2011 - 2018
Read More

Thursday, 12 June 2014

Membrane Separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

01:26 No comments
According to a new market report published by Transparency Market Research "Membrane separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global membrane separation market was valued at USD 19.0 billion in 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 39.2 billion in 2019.

Browse the full Membrane separation Market Report at http://www.transparencymarketresearch.com/membrane-separation-market.html

The increasing demand for clean processed water and mandatory government regulation to provide clean drinking water is propelling the water processing industry at present. Membrane separation is one of the most popular methods used for cleaning water. Shifting from chemical to physical treatments of water is also a major driver as chemical treatments are perceived as an environmentally unclean technology with associated disposal costs. Additional awareness of water scarcity has influenced the demand for water reuse in water stressed areas. Governments and municipal authorities are increasingly waking up to the effects of environmental degradation on the economy. Mandatory adherence of certain environmental standards by the national government such as the Clean Water Act especially in areas with water scarcity have influenced the demand for better water treatment technology, including membrane separation technology.


Worldwide industrial expansion and growing population are propelling the demand for better water treatment technology, providing growth opportunity for the overall market of membrane separation technology. Additionally, the oil and petroleum industry is well established in countries such as Italy and Germany which involve membrane separation technology for liquid separation. Membrane separation technology is majorly divided under four major processes, microfiltration, ultrafiltration, nanofiltration and reverse osmosis. Microfiltration dominates the market with more than 35% global market share. Whereas water & wastewater dominates the end-user market with 36% global market shares in terms of uses. The global membrane separation market grew from USD 19.0 billion in 2010 to USD 21.2 billion in 2013.
European membrane market is expected to reach USD 13.8 billion in 2019. In 2012 water & wastewater sector was the major end-user of membrane separation technology and is expected to increase at a CAGR of 11.1% during 2013-19. The membrane separation technology market is fragmented with several players in the market supplying membrane separation to the end-users in the market.


Membrane separation is used by various sectors such as water and wastewater treatment and industrial and healthcare sectors. Most of the companies produce different types of membrane products such as microfiltration, nanofiltration, ultrafiltration and reverse osmosis and sell them globally. Major companies that are operating globally and manufacturing all four products are Koch Membrane Systems Inc., Pall Corporation, Merck Millipore, 3M Company, Degremont SA, Dow Chemical Company, GEA Filtration, Nitto Denko Corporation, Époque Water Technologies and Veolia Environnement.

Read More

Thursday, 5 June 2014

Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

04:09 No comments
Smoking Cessation and Nicotine De-addiction Products Market 
According to a new market report published by Transparency Market Research "Smoking Cessation and Nicotine De-addiction Products Market (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global smoking cessation and nicotine de-addiction productsmarket was valued at USD 5.1 billion in 2012 and is expected to grow at a CAGR of 18.7% from 2013 to 2019, to reach an estimated value of USD 16.02billion in 2019.

Smoking cessation is a process of discontinuing smoking achieved by the use of medication. It may also be coupled with assistance of healthcare professionals, counselling and psychotherapy. The demand for smoking cessation products is high and is continuously rising as it caters to the needs of people addicted to nicotine and rising healthcare awareness amongst the smokers. The global smoking cessation and nicotine de-addiction products market is segmented on the basis of product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. This market is sustained by large number of people wanting to quit smoking.

Browse Global Smoking Cessation and Nicotine De-addiction Products Market with full TOC at http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html

The nicotine patches and lozenges market is driven by its ease of use and non-prescription sale. Nicotine sprays and inhalers on the other hand are less preferred due to their high cost and less popularity. However, increased promotional activities and effective distribution is expected to boost their market growth in the near future. The major players in the NRT products market include Johnson and Johnson, GSK, Cipla and Novartis.
Smoking cessation drug therapy market is expected to witness a decline in revenue across the globe, by the end of the forecast period due to patent expiration of the key revenue generating drugs Zyban (bupropion)  in 2013 and Chantix/Champix (varenicline) in 2018 (which will impede market growth toa lower extent). The loss of patent and marketing exclusivity will lead to a drastic reduction in revenue and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. The leading players in the drug therapy market are GSK and Pfizer.


Geographically, North America dominates the global smoking cessation and nicotine de-addiction products market. The North American market for smoking cessation products was valued at USD 1,958.8 million in the year 2012. An increase in cigarette costs is expected to reduce smoking rates significantly, especially in adolescents. According to the CDC, a 10% rise in cigarettes cost can cut around 4% of young adults craving cigarette consumption. The European market held the second largest share worldwide, in 2012. WHO reports that European countries have widely adopted bans on tobacco advertising, promotion on national/international television and radio, billboards and outdoor advertising, local magazines and newspapers. However, some countries in Europe still lack in implementing measures of the WHO Framework Convention on Tobacco Control (FCTC).


Raising taxes to increase the cost of cigarettes can reduce tobacco use, cut smoking rates, and ultimately save lives. Smoking prevalence has been varying across the globe with many developing countries witnessing rapid increase in the prevalence rate, which will create huge health problems for the future if left unchecked. Demand for lifestyle drugs in emerging countries is witnessing rapid growth due to factors including growing health awareness, increase in population, and development of public healthcare systems, among others. This is driving people towards quitting smoking by adopting smoking cessation products. A study in the Eastern Mediterranean Health Journal, published in 2012, reported that nicotine containing medications are not available in one third of the developing countries, which include the Middle East and Africa. Moreover, accessibility of non-nicotine containing medications such as bupropion and varenicline is also extremely low. Increased attention and resources are needed to address lack of smoking cessation services as well as access to nicotine containing medications in these regions.

Read More

Wednesday, 28 May 2014

Narcolepsy Market - Global Industry Analysis, Size, Trends And Forecast, 2013 – 2019

02:48 No comments
Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Narcolepsy Marke ". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors.

Browse Full Report with TOC:
http://www.transparencymarketresearch.com/narcolepsy-market.html

Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is often confused with insomnia. Other major symptoms of this disorder include, cataplexy, sleep paralysis, hypnagogic hallucinations, automatic behavior and night weakness.

Some of the major factors driving the growth of this market include increasing prevalence of various sleep disorders including narcolepsy, rising awareness about the disorder and increasing demand for advanced therapeutics and diagnostics.Narcoleptic disorder is equally prevalent to Parkinson’s disease or multiple sclerosis and is more prevalent than cystic fibrosis. There are more than 3 million people suffering from this disorder worldwide.Rising awareness about the disorder, and the resultant increase in demand for new and innovative drugs and other treatment optionswill lead to the growth of this market in future.

Geographically, North America dominates the global narcolepsy market followed by Europe. Major factors responsible for their dominance are high prevalence rate of narcolepsy in these regions. U.S. alone accounts for more than 200,000 narcoleptic individuals and is also characterized by high awareness levels among the general population. Asia-Pacific region exhibited fastest growth in this market due to increasing awareness levels about the disease and its treatment options and increasing spending power of the population. 

Some of the key players operating in this market are Addrenex Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., BIOPROJET, Cephalon, Inc., Evotec AG, Graymark Healthcare, Inc., Hypnion, Inc., Jazz Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World 
This report provides comprehensive analysis of 

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

More Reports on Pharmaceutical Market: 
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Browse Market Research Report:-
http://www.tmrblog.com/

http://marketingfirmblog.wordpress.com/

About Us:-

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us

Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Read More
Subscribe to: Posts (Atom)